{"name":"Vyne Therapeutics Inc.","slug":"vyne-therapeutics-inc","ticker":"","exchange":"","domain":"vynetherapeutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"FMX-103 3%","genericName":"FMX-103 3%","slug":"fmx-103-3","indication":"Other","status":"phase_2"},{"name":"Matching Placebo Tablets","genericName":"Matching Placebo Tablets","slug":"matching-placebo-tablets","indication":"Other","status":"phase_3"},{"name":"Serlopitant Low Dose","genericName":"Serlopitant Low Dose","slug":"serlopitant-low-dose","indication":"Other","status":"phase_2"},{"name":"FMX-101","genericName":"FMX-101","slug":"fmx-101","indication":"Other","status":"phase_1"},{"name":"FMX-103 1.5%","genericName":"FMX-103 1.5%","slug":"fmx-103-1-5","indication":"Other","status":"phase_2"},{"name":"Serlopitant High Dose","genericName":"Serlopitant High Dose","slug":"serlopitant-high-dose","indication":"Other","status":"phase_2"},{"name":"VPD-737","genericName":"VPD-737","slug":"vpd-737","indication":"Other","status":"phase_2"},{"name":"VYN201 Gel","genericName":"VYN201 Gel","slug":"vyn201-gel","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"FMX-101, 4% minocycline foam","genericName":"FMX-101, 4% minocycline foam","slug":"fmx-101-4-minocycline-foam","indication":"Acne vulgaris","status":"phase_3"},{"name":"FMX101","genericName":"FMX101","slug":"fmx101","indication":"Moderate acne vulgaris","status":"phase_3"},{"name":"FMX103 1.5%","genericName":"FMX103 1.5%","slug":"fmx103-1-5","indication":"Acne vulgaris","status":"phase_3"},{"name":"FMX103 minocycline foam 1.5%","genericName":"FMX103 minocycline foam 1.5%","slug":"fmx103-minocycline-foam-1-5","indication":"Acne vulgaris","status":"phase_3"},{"name":"Vehicle Foam","genericName":"Vehicle Foam","slug":"vehicle-foam","indication":"Topical dermatological conditions (specific indication dependent on active ingredient formulated in vehicle)","status":"marketed"}]}],"pipeline":[{"name":"FMX-103 3%","genericName":"FMX-103 3%","slug":"fmx-103-3","phase":"phase_2","mechanism":"FMX-103 is a topical tetracycline antibiotic that provides anti-inflammatory and antimicrobial effects against acne-causing bacteria.","indications":[],"catalyst":""},{"name":"Matching Placebo Tablets","genericName":"Matching Placebo Tablets","slug":"matching-placebo-tablets","phase":"phase_3","mechanism":"A matching placebo tablet contains inert ingredients designed to be indistinguishable from an active pharmaceutical formulation for use as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Serlopitant Low Dose","genericName":"Serlopitant Low Dose","slug":"serlopitant-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FMX-101","genericName":"FMX-101","slug":"fmx-101","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FMX-101, 4% minocycline foam","genericName":"FMX-101, 4% minocycline foam","slug":"fmx-101-4-minocycline-foam","phase":"phase_3","mechanism":"Minocycline, a tetracycline antibiotic, reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators.","indications":["Acne vulgaris"],"catalyst":""},{"name":"FMX-103 1.5%","genericName":"FMX-103 1.5%","slug":"fmx-103-1-5","phase":"phase_2","mechanism":"Topical minocycline formulation that provides anti-inflammatory and antimicrobial effects through inhibition of bacterial protein synthesis and modulation of inflammatory pathways.","indications":[],"catalyst":""},{"name":"FMX101","genericName":"FMX101","slug":"fmx101","phase":"phase_3","mechanism":"FMX101 is a topical foam formulation of minocycline that reduces bacterial colonization and inflammation in acne-prone skin.","indications":["Moderate acne vulgaris"],"catalyst":""},{"name":"FMX103 1.5%","genericName":"FMX103 1.5%","slug":"fmx103-1-5","phase":"phase_3","mechanism":"FMX103 is a topical minocycline formulation that reduces bacterial colonization and inflammatory mediators in the skin.","indications":["Acne vulgaris","Rosacea"],"catalyst":""},{"name":"FMX103 minocycline foam 1.5%","genericName":"FMX103 minocycline foam 1.5%","slug":"fmx103-minocycline-foam-1-5","phase":"phase_3","mechanism":"Minocycline, a tetracycline antibiotic, reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Serlopitant High Dose","genericName":"Serlopitant High Dose","slug":"serlopitant-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VPD-737","genericName":"VPD-737","slug":"vpd-737","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VYN201 Gel","genericName":"VYN201 Gel","slug":"vyn201-gel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vehicle Foam","genericName":"Vehicle Foam","slug":"vehicle-foam","phase":"marketed","mechanism":"Vehicle Foam is a topical foam formulation designed to deliver active pharmaceutical ingredients to the skin surface for localized therapeutic effect.","indications":["Topical dermatological conditions (specific indication dependent on active ingredient formulated in vehicle)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE14Y2I5b204bGpVVEREdFhGZlAxOEkyWFZoLXEwUnY2cW1Jc0tIMWlSQkRaVDhib21tbnV1QkhYNjZpOUZpaHR4bW1Kb1FKRXBoSk5Id19EVmk5TDFuRlM3OF9nN2xIZjJFWU1fYllR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Vyne Therapeutics Inc (VYNE) - Stock Titan","headline":"If You Invested $1,000 in Vyne Therapeutics Inc (VYNE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONWtkS1BCNmtmc1QyMldwbUhzZ2NraUlkRjdOOXZOU0FLSDRnYzV2bm9DdF8yTGUyUWRHRnhha2xxV2M0SzFOdU9ZQTVGVWFRaEYyVUptYXE4a1pXdUR6akh3ZU1nODQtRDd3UmtsU25HMUtuZ0JUem5GdWk2Q2o3ZlhVaWFIenJWY0Vkb2NMeFlhc1E?oc=5","date":"2025-12-18","type":"deal","source":"The Pharma Letter","summary":"VYNE to merge with Yarrow in $200 million deal - The Pharma Letter","headline":"VYNE to merge with Yarrow in $200 million deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQMkFqR3R5Mmw4WWdUTWVvN0xYM3R4YjVta1RrN0hZSnlNci02aHUtM2FVWEY3TXB2bDk2bEU5Sy1FOVZBZ0JScmtLdjZMc2lfMU9WNVIxblVBSkt2ZGFrNjVsdVNoU0RoS1o0MU9wNnh3RU84ZFJYWVFld1NmY3l2UmtRNnhJdFVpbnNneGhlQWwyNnpKa1Fyak1wVmNiTVgzUjNPdFhLZ0xIZF9FclItdmt0cG02UlVGM1pSdWEtZ2NZTUZWMEYySlJSbk82R090X0ZaZWw0dzluYVhkS3kzTXJTZTBySmJHNXFIcWF4QUNrQXY0UW9ROVhwaVVjTDFUUEhFMHAtaldMemhHTC1kOUVKRmZnRWFKaXZoRm1hOA?oc=5","date":"2025-08-14","type":"trial","source":"GlobeNewswire","summary":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma - GlobeNewswire","headline":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQ0VxTE5TZ1Rsc1JGLWljb1NBRDRadk9YdHpvVGpHeG1nU011OHRuOVVmbm44OUozVmQyamVHbWxvdjU4T3NUMVd6OUZnY0FyS3RpODBES1NPSEFtSzZMS1NoX2hHYWhrcVozRF80bXc0ZGdPZm5PeWo1bVN1MXJpOUliZTAwMnc5OGhWLXBLRnYtaHM4bzFoTThOamlTOGp5QXlCZ0hYM2s4dmpQb3Z4Wk5tOVBsNUZmMkZtZmo2dDk?oc=5","date":"2025-07-30","type":"trial","source":"Stock Titan","summary":"VYNE's Vitiligo Drug Shows Mixed Results: 43% Improvement in High-Dose Group Despite Trial Miss - Stock Titan","headline":"VYNE's Vitiligo Drug Shows Mixed Results: 43% Improvement in High-Dose Group Despite Trial Miss","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOQ2F0dGRRUjljNGVkcWdCVmFudndjTFNTY0lHdWkwdnlXb1hRYXRrOW1YeFpSd1oxd1hIbzdyUUVZdHlFTGJjQmJhaFZzTXZ0MGdDVFZYb0Nfa3dmTi1CWlFTaTZDbWc0cXp1UmYzSWJuaTJfRDJRMmZRV21SeU11SktidHdCc3pwdzlsNWJUVi1XNXlNTTRXY0RKWEFUODB0ZHFGOUI1WQ?oc=5","date":"2025-07-28","type":"trial","source":"Seeking Alpha","summary":"Vyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b Readout (NASDAQ:VYNE) - Seeking Alpha","headline":"Vyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b Readout (NASDAQ:VYNE)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-27","type":"pipeline","source":"simplywall.st","summary":"We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - simplywall.st","headline":"We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTFBncHp3WFVlMDAxdFZObFd4NFhwemFGbDVTQjZLeFZ2M2E0MWp2SHp6VEdaNkZVc3N2Zi1TT1pOX19ta2h2ZlhWVA?oc=5","date":"2025-05-13","type":"pipeline","source":"Intellectia AI","summary":"VYNE Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI","headline":"VYNE Stock: Price, Forecast, Financials & AI Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBOM0l2MzJyVlh3ZjhiaWQyc215Y0kydGZ4eFl4Q0c0akViRGF3RVA2VkJpNkFaeWZuT2pDcUp4cXF3Y19BbzJuZkpRbW1hR2I3TzhHX1RGRWdyUjNmVVVmZ0o2b1JIbDh0NE5fQ2JJdzM1VTg?oc=5","date":"2025-01-07","type":"trial","source":"Clinical Trials Arena","summary":"VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Clinical Trials Arena","headline":"VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1Va3JBYzBRazBkaHlaYk5tZmNING4wVzYtV0g4UktURmhlNXBCelNpNkRhbTRQWkkydXZJSUJ2X2Y2WUYwUndGeXVJWEYyV3dxcW9wLXVyUzRfcmNuTmhGbVI0cDBkb2w3M1h2OXRPTmk?oc=5","date":"2024-12-23","type":"pipeline","source":"Built In","summary":"20 Pharmaceutical Companies in Israel to Know - Built In","headline":"20 Pharmaceutical Companies in Israel to Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBJZXF4aE9JS29uY2Z3SW4xSUoxRmF2UG9ZOVcwMTdiV0F4LVFETGlHbHh1NTNTWUNueXZic25IS0FBbGN4LWw1YXpSSkppVHVO?oc=5","date":"2023-10-31","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9MU3VaQzktcE1IVENMVndlR01nS0RJMFd2blk2WkhuX2pBSzJqLS1YYXVNSGlFa1dCazU3UW9mMV96QjZCZEt5Q3VBeVpEZzA5ZEhfSjg3OU1sWUVFMmln?oc=5","date":"2020-09-10","type":"pipeline","source":"ChartMill","summary":"VYNE Stock Price, Quote & Chart | VYNE THERAPEUTICS INC (NASDAQ:VYNE) - ChartMill","headline":"VYNE Stock Price, Quote & Chart | VYNE THERAPEUTICS INC (NASDAQ:VYNE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9HQjNfUWhPZjBWY1pQWU1CNVVwYkVtcTh2dFkwMDg0UFBZalJIa3BLaVZuZkUtR0NjVkRpd1JRcUx5b0VUOWdoT3QxeDZScGNyYmMxWUpPcWljRTVC?oc=5","date":"2020-09-09","type":"pipeline","source":"TradingView","summary":"VYNE Stock Price and Chart — NASDAQ:VYNE - TradingView","headline":"VYNE Stock Price and Chart — NASDAQ:VYNE","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_2":6,"phase_3":5,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}